| Autor: |
Smith, Vernon M., Mead Jr., Joseph A., Idea, Braulio V., Mallari, Ruben P. |
| Předmět: |
|
| Zdroj: |
American Journal of Gastroenterology (Springer Nature); Jan1963, Vol. 39 Issue 1, p52-60, 9p, 1 Diagram, 2 Charts, 3 Graphs |
| Abstrakt: |
A new anticholinergic drug, pentapiperide methylsulfate, was studied by double-blind technic from the standpoints of its effect upon basal gastric secretion in human subjects, its clinical effectiveness in relieving the symptoms of peptic ulcer, and the occurrence of associated side-effects. Significant suppression of gastric acid and elevation of gastric pH values followed administration of 20 mg. doses of the drug in 10 of 18 unselected subjects. Patients with active peptic ulcers experienced a lessening or a complete remission of symptoms of pain, heartburn and sour eructation during therapy with 15 mg. of the drug four times daily. Side-effects of dry mouth, visual blurring and urine retention occurred infrequently and mildly. "Analyses of 40 gastric aspiration specimens obtained from 20 patients with active peptic ulcers two hours after a morning dose of 15 mg. of pentapiperide methylsulfate revealed gastric achlorhydria and a pH greater than 4.5 in 55 per cent. Pentapiperide methylsulfate was found to be a potent anticholinergic drug. It afforded significant relief of the symptoms of active peptic ulcer. Side-effects which were sometimes associated with its use were mild and reversible, and never necessitated drug withdrawal in view of some individual variation in responsiveness to the drug, for optimum effectiveness, it is recommended that dosage be increased, if necessary, beyond the 15 to 20 mg. levels used in this study; in order to evoke mild mouth dryness, but not visual blurring nor urine retention. It is concluded that pentapiperide methylsulfate is a clinically effective drug. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
